A3: Please consult the ingredient list and your healthcare provider to determine suitability
With a 2026 launch on the horizon, this medication could be a major shift in the GLP-1 landscape, giving patients another powerful tool to fight obesity and diabetes without an injection
Wegovy for weight loss (max dose 2.4 mg/week)
Approved GLP-1 and GIP/GLP-1 medications have completed FDA review for specific uses
Some patients express concern over the cyanide in cyanocobalamin
In PNA mice, GLP1/E therapy caused upregulation of pathways involved in the metabolism of non-coding RNA, estrogen-dependent gene expression, autophagy, vesicle-mediated transport, and signaling by nuclear receptors, whereas proteins related to inflammation (ROS and RNS production in phagocytes), cellular response to starvation, signaling by insulin receptor, apoptosis, and immune system were downregulated